Alx Oncology Holdings (ALXO) Cash from Operations (2019 - 2026)
Alx Oncology Holdings recorded quarterly Cash from Operations of 18648000.0 in Q1 2026, up 1.75% quarter-over-quarter from 18980000.0 in Q4 2025, and up 24.39% year-over-year from 14991708.19 in Q1 2025.
Alx Oncology Holdings' Cash from Operations history runs 8 years deep, the most recent figure standing at 18648000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 24.39% year-over-year to 18648000.0; the TTM figure through Mar 2026 stood at 78127000.0 (up 28.09% YoY), while the FY2025 annual figure was 84142000.0, up 30.98% from the prior year.
- Cash from Operations came in at 18648000.0 for Q1 2026 at Alx Oncology Holdings, up from 18980000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 16998000.0 in Q2 2022 to a low of 39678000.0 in Q4 2023.
- A 5-year average of 26134647.06 and a median of 25376000.0 in 2024 frame the typical range for Cash from Operations.
- Across the five-year window, Cash from Operations plunged 302.61% in 2022 and soared 40.77% in 2025, its largest moves.
- Alx Oncology Holdings' Cash from Operations stood at 20668000.0 in 2022, then tumbled by 91.98% to 39678000.0 in 2023, then rose by 19.23% to 32046000.0 in 2024, then soared by 40.77% to 18980000.0 in 2025, then climbed by 1.75% to 18648000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 18648000.0, 18980000.0, and 17093000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Alx Oncology Holdings | 189.80 Mn | 49.48 Mn | - | -18.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.65 Mn |
| Mar 31, 2026 | -18.65 Mn |
| Dec 31, 2025 | -18.98 Mn |
| Dec 31, 2025 | -18.98 Mn |
| Sep 30, 2025 | -17.09 Mn |
| Sep 30, 2025 | -17.09 Mn |
| Jun 30, 2025 | -23.41 Mn |
| Jun 30, 2025 | -23.41 Mn |
| Mar 31, 2025 | -24.66 Mn |
| Mar 31, 2025 | -24.66 Mn |
| Dec 31, 2024 | -32.05 Mn |
| Dec 31, 2024 | -32.05 Mn |
| Sep 30, 2024 | -25.38 Mn |
| Sep 30, 2024 | -25.38 Mn |
| Jun 30, 2024 | -26.57 Mn |
| Jun 30, 2024 | -26.57 Mn |
| Mar 31, 2024 | -37.92 Mn |
| Mar 31, 2024 | -37.92 Mn |
| Dec 31, 2023 | -39.68 Mn |
| Dec 31, 2023 | -39.68 Mn |
| Sep 30, 2023 | -31.16 Mn |
| Sep 30, 2023 | -31.16 Mn |
| Jun 30, 2023 | -31.71 Mn |
| Jun 30, 2023 | -31.71 Mn |
| Mar 31, 2023 | -27.82 Mn |
| Mar 31, 2023 | -27.82 Mn |
| Dec 31, 2022 | -20.67 Mn |
| Dec 31, 2022 | -20.67 Mn |
| Sep 30, 2022 | -30.88 Mn |
| Sep 30, 2022 | -30.88 Mn |
| Jun 30, 2022 | -17.00 Mn |
| Jun 30, 2022 | -17.00 Mn |
| Mar 31, 2022 | -20.67 Mn |
| Mar 31, 2022 | -20.67 Mn |
| Dec 31, 2021 | -17.49 Mn |
| Dec 31, 2021 | -17.49 Mn |
| Sep 30, 2021 | -24.86 Mn |
| Sep 30, 2021 | -24.86 Mn |
| Jun 30, 2021 | -20.62 Mn |
| Jun 30, 2021 | -20.62 Mn |
| Mar 31, 2021 | -5.14 Mn |
| Mar 31, 2021 | -5.14 Mn |
| Dec 31, 2020 | -13.62 Mn |
| Dec 31, 2020 | -13.62 Mn |
| Sep 30, 2020 | -9.55 Mn |
| Sep 30, 2020 | -9.55 Mn |
| Jun 30, 2020 | -6.16 Mn |
| Jun 30, 2020 | -6.16 Mn |
| Mar 31, 2020 | -8.96 Mn |
| Mar 31, 2020 | -8.96 Mn |
| Dec 31, 2019 | -2.87 Mn |
| Dec 31, 2019 | -2.87 Mn |
| Sep 30, 2019 | -3.19 Mn |
| Sep 30, 2019 | -3.19 Mn |